Evidence map›Paper›PMID 36041689›Full record

ArticleJournal of advanced research2023

Antibody-conjugated and streptomycin-chitosan oligosaccharide-modified gold nanoshells for synergistic chemo-photothermal therapy of drug-resistant bacterial infection.

Panchanathan Manivasagan, Fazlurrahman Khan, Durai Rajan Dhatchayeny, Sumin Park, Ara Joe, Hyo-Won Han, Sun-Hwa Seo, Thavasyappan Thambi, V H Giang Phan, Young-Mog Kim and 3 more

Abstract read
In one paragraph

Article in Journal of advanced research, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Review
  2. NIR-Assisted Multimodal Strategies for Enhanced Antibacterial Therapy.Small (Weinheim an der Bergstrasse, Germany) · 2026
    Review
  3. Article
  4. Review
  5. Review
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Panchanathan ManivasaganDepartment of Applied Chemistry, Kumoh National Institute of Technology, Daehak-ro 61, Gumi, Gyeongbuk 39177, Republic of Korea.
Fazlurrahman KhanResearch Center for Marine Integrated Bionics Technology, Pukyong National University, Busan 48513, Republic of Korea.
Durai Rajan DhatchayenyDepartment of Information and Communications Engineering, Pukyong National University, Busan 48513, Republic of Korea.
Sumin ParkIndustry 4.0 Convergence Bionics Engineering, Pukyong National University, Busan 48513, Republic of Korea.
Ara JoeDepartment of Applied Chemistry, Kumoh National Institute of Technology, Daehak-ro 61, Gumi, Gyeongbuk 39177, Republic of Korea.
Hyo-Won HanDepartment of Applied Chemistry, Kumoh National Institute of Technology, Daehak-ro 61, Gumi, Gyeongbuk 39177, Republic of Korea.
Sun-Hwa SeoDepartment of Applied Chemistry, Kumoh National Institute of Technology, Daehak-ro 61, Gumi, Gyeongbuk 39177, Republic of Korea.
Thavasyappan ThambiSchool of Chemical Engineering, Theranostic Macromolecules Research Center, Sungkyunkwan University, Suwon 16419, Republic of Korea.
V H Giang PhanBiomaterials and Nanotechnology Research Group, Faculty of Applied Sciences, Ton Duc Thang University, Ho Chi Minh City 70000, Viet Nam.
Young-Mog KimResearch Center for Marine Integrated Bionics Technology, Pukyong National University, Busan 48513, Republic of Korea.
Chang-Seok KimDepartment of Cogno-Mechatronics Engineering, Pusan National University, Busan 46241, Republic of Korea.
Junghwan OhIndustry 4.0 Convergence Bionics Engineering, Pukyong National University, Busan 48513, Republic of Korea; New-senior Healthcare Innovation Center (BK21 Plus), Pukyong National University, Busan 48513, Republic of Korea; Department of Biomedical Engineering, Pukyong National University, Busan 48513, Republic of Korea. Electronic address: jungoh@pknu.ac.kr.
Eue-Soon JangDepartment of Applied Chemistry, Kumoh National Institute of Technology, Daehak-ro 61, Gumi, Gyeongbuk 39177, Republic of Korea. Electronic address: euesoon@kumoh.ac.kr.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Despite the many advanced strategies that are available, rapid gene mutation in multidrug-resistant bacterial infections remains a major challenge. Combining new therapeutic strategies such as chemo-photothermal therapy (PTT) with high antibacterial efficiency against drug-resistant Listeria monocytogenes (LM) is urgently needed. Here, we report synergistic chemo-PTT against drug-resistant LM based on antibody-conjugated and streptomycin-chitosan oligosaccharide-modified gold nanoshells (anti-STR-CO-GNSs) as all-in-one nanotheranostic agents for the first time, which was used for accurate antibacterial applications. The anti-STR-CO-GNSs showed excellent photothermal conversion efficiency (31.97 %) and were responsive to near-infrared (NIR) and pH dual stimuli-triggered antibiotic release, resulting in outstanding chemo-photothermal effects against LM. In vitro chemo-photothermal effect of anti-STR-CO-GNSs with laser irradiation caused a greater antibacterial effect (1.37 %), resulting in more rapid killing of LM and prevention of LM regrowth. Most importantly, the mice receiving the anti-STR-CO-GNSs with laser irradiation specifically at the sites of LM infections healed almost completely, leaving only scars on the surface of the skin and resulting in superior inhibitory effects from combined chemo-PTT. Overall, our findings suggest that chemo-PTT using smart biocompatible anti-STR-CO-GNSs is a favorable potential alternative to combat the increasing threat of drug-resistant LM, which opens a new door for clinical anti-infection therapy in the future.

Indexed as

Bacterial InfectionsChitosanHyperthermia, InducedNanoshellsAnimalsAnti-Bacterial AgentsGoldMiceOligosaccharidesPhototherapyPhotothermal TherapyStreptomycinAnti-Bacterial AgentsChitosanGoldOligosaccharidesStreptomycinChemotherapyChitosan oligosaccharideDrug-resistant bacteriaGold nanoshellsPhotothermal therapy

Identifiers

PMID36041689
PMCPMC10248803

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.